The header image of a vintage laboratory for today’s offering is courtesy of Adobe Stock and Google Images.

Health Friday is a series devoted to information about Big Pharma, vaccines, general health, and associated topics.

There are Important Notifications from our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Yours Truly has checked today’s offering for AI-generated content. To the best of her knowledge and belief, there is none, except perhaps for AI-generated images embedded in certain links. If readers wish to post AI-generated content to the discussion thread of today’s offering, they must cite their source. Thank you.

Today’s offering contains more proof that, even though the United States government has “officially” paused Gain-of-Function experiments, these experiments are still continuing. Please see: https://www.theqtree.com/2025/08/29/health-friday-8-29-2025-open-thread-gain-of-function-research-is-still-going-on/. This time, there are two separate facilities in the United States that are performing the Gain-of-Function (GoF) work. The first is the new “bat experiments lab” at Colorado State University at Fort Collins, CO. The second is the laboratory at Georgia State University at Atlanta, GA. Bear with Yours Truly: the end of the post is the “punch line.” Yours Truly makes it clear at the start that there is no intent to “cast aspersions” on the research of any of the persons mentioned in today’s offering, or on the current Acting Director of the NIAID.

To begin, the Colorado State University facility. Please see: https://www.theburningplatform.com/2025/09/15/gain-of-function-is-alive-and-thriving-in-the-united-states/, by Patti Johnson, 9 September 2025. This regards a 14,000 square foot “bat research facility” that was added to an already-exiting research lab building at Colorado State University (CSU.) The majority of the funding for this “bat research lab”, $6.7 million dollars, came from NIH grant C06OD032019 (https://source.colostate.edu/csu-awarded-6-7-million-nih-award-for-research-facility-focused-on-bat-health-disease-transmission/, 7 October 2021. CSU already had a 38,000 square foot research facility in which the university had invested $22 million dollars, and which had opened in 2020: https://cvmbs.source.colostate.edu/more-than-a-building-the-center-for-vector-borne-infectious-diseases-marks-a-new-era-in-research/, 11 December 2020 (which, by the way, is the same date that the FDA granted the initial Emergency Use Authorization for the Pfizer-BioNTech modRNA COVID-19 “vaccine” BNT162b2 to be used in the United States.) In “The Center for Vector Borne Infectious Diseases” at CSU, the professors “mix in” with students in the labs. This facility has 10 labs and employs more than 90 personnel. The labs are all BSL-2 labs. This situation, in and of itself, raises two questions: One, why are students allowed to “mix in” with the professors in these labs? And, Two, if these labs are handling / experimenting with, infectious diseases pathogens, why are the labs only BSL-2 safety level? Please see: https://ghphipps.com/colorado-state-university-center-for-vector-borne-infectious-disease/. A screenshot from this article is below:

GH Phipps was the construction company for the facility.

However, the “new bat research facility” is the separate 14,000 square foot building: https://yellowscene.com/2024/09/19/csu-to-build-taxpayer-funded-facility-for-bat-breeding-and-research/, 19 September 2024. This was the facility built with the NIH grant of $6.7 million dollars. This building is located here: 3105 Rampart Rd., Ft. Collins, CO, 5 minutes from downtown Fort Collins.

And, guess what? The “new bat research facility” in Fort Collins also has BSL-2 level labs: A screenshot from the Yellow Scene article is below:

The entire situation at CSU raises other questions: One, will professors ALSO “mix in” with students at this “bat breeding and research” facility? And, Two, why is CSU attempting to be the “United States version” of the Wuhan Institute of Virology, which is what the “new bat research facility” at CSU appears to be?

And, now, turning to the second issue, the continuing Gain-of-Function experiments with Avian Influenza viruses going on in the United States —- this time, at Georgia State University in Atlanta. Please see: https://jonfleetwood.substack.com/p/us-and-south-korean-scientists-lab, “U.S. and South Korean Scientists Lab-Engineer Frankenstein Bird Flu Viruses in Georgia: Journal ‘Virology'”. 14 September 2025. The GoF experiments at GSU, supported by an NIH grant, were performed by South Korean scientists who are ALSO be professors at Georgia State University, with a couple of said professors ALSO having ties to South Korean institutions. Yours Truly will also present **interesting information** regarding the scope of this research at GSU by one particular author of the paper just cited. Please see the screenshot below, from the Fleetwood article:

The paper cited in the Fleetwood article is here: https://doi.org/10.1016/j.virol.2025.110674, “Interferon-y receptor signaling is critical for balanced immune activation and protection against influenza after vaccination”, Sang-Moo Kang, et al., 6 September 2025. A screenshot of the list of the paper’s authors and their affiliations is below, from the paper itself:

Note that the TITLE of the paper does NOT mention what type of influenza was the study subject (in this case, it was Avian Influenza.) More on this aspect later on in today’s offering.

Following are screenshots from sections of the paper that are available online. Note: the entire paper is available only through institutional access, or through paid access.

From the Introduction of the paper:

And, the from the funding section of the paper:

The NIH grant went to Sang-Moo Kang, the principal investigator. Please see: https://www.gsu.edu/2021/06/04/biomedical-sciences-researcher-gets-2-7-million-federal-grant-to-study-seasonal-and-universal-vaccination-in-aged-populations/. This was the NIH grant AI154656 cited above. A screenshot of this article is below — in its entirety, as there are several “clues” in it:

Note the “clues”: “universal vaccination”; aged populations”; “multiple influenza proteins”; “translational science”; “cross protective efficacy.” However, the “multiple influenza proteins” that were experimented with in the paper cited above were not regular “seasonal flu viruses” — they were strains of H5N1, the Avian Influenza virus.

It appears that Dr. Kang has also used some of the AI154656 NIH grant on other research and papers, such as for this paper: https://doi.org/10.1016/j.vaccine.2025.127206, “Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection”, Sang-Moo Kang, et al., Version of Record 7 May 2025. Again, this is “Dr. Kang and his gang” at work; the exception here is that the researchers for this paper are all affiliated only with Georgia State University. And, again, the entire paper is available only through institutional access or through paid access. Keep in mind the emphasis of the paper on “intranasal vaccine delivery.”

This particular paper is the result of Dr. Kang’s, et al., research using another “mixture” of influenza viruses — H1N1 (“swine flu”, a subtype of Influenza A), plus H3N2 (a non-human influenza virus in pigs that can infect humans, https://oklahoma.gov/health/health-education/acute-disease-service/disease-information/influenza-a-h3n2-variant-.html), plus H5N1 Avian Influenza. Screenshots from the “snippets” of this paper that are available online are below: the Abstract; a portion of the Viruses section; and, a portion of the Acknowledgements section:

It appears that the paper purports to prove that the intranasal method of “vaccine delivery” is superior to the current intramuscular (injection) method. It is also clear that experiments that were performed were Gain-of-Function work — this time, combining various Influenza A subtypes (“swine flu” that infects humans; “swine flu” that can infect humans; and, Avian Influenza); plus, Influenza B. It is also clear that these experiments were designed to have maximum effect on the CD4 – CD8 cells and the IgG system. By the way, neuraminidase is an important component in the spread of influenza virus in human lungs. Interferon-y (IFN-y) is an element that is important in the regulation of immune and inflammatory responses, among other functions.

**** There is one more paper by “Dr. Kang and Gang” at GSU that bears scrutiny; this one, published in July 2024: https://doi.org/10.1038/s41467-024-50087-5, “Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines”, Sang-Moo Kang, et al., 10 July 2024. This paper describes Gain-of-Function experiments not only with various influenza viruses (H3N2 and H7N9 [H7N9 is an Avian Influenza virus that is particularly lethal to humans who get infected with it]); it also describes what can only be Gain-of-Function experiments with “delivery methods” for the TWO different kinds of influenza “vaccines” that use EITHER lipid nanoparticles, OR use PHC (a protein-based nanoparticle.) Several screenshots from this paper are below, starting with the Abstract; then, Figure 1.; followed by a portion of the Discussion section:

The LNPs (lipid nanoparticles) used in the “mRNA initial series vaccine” in the experiments in the above paper are: DOTMA (cationic lipid, used in gene therapies, enhances gene transfection); DOPE (enhances intracellular “delivery” of the “vaccine” ingredients); and, DMG-PEG2000 (nanoparticle version of polyethylene glycol; one of the two LNPs in the Moderna modRNA COVID-19 “vaccines”, the other being SM-102.)

It appears that this paper describes how a “multi-delivery method” of a 2-injection series of a modRNA influenza “vaccine”, followed by a 1-dose “booster” of an intranasal modRNA influenza “vaccine”, is the “optimal” method for “cross-protection” against infection.

The “PUNCH LINE” section of today’s offering follows:

**** In fact, it appears that the above paper claims that modRNA influenza “vaccine” intramuscular injection (IM injection) is now to be considered as “priming the pump” for the subsequent use of modRNA intranasal delivery of the influenza “vaccine” in order to have “sufficient protection” against infection. In other words — TWO types of “delivery methods” need to used.

The above paper was funded by NIH grants R01AI101047 and R01AI143844 to “Dr. Kang and Gang” researcher Bao-Zhong Wang. Dr. Wang, by the way, seems to be from Communist China, having earned his PhD from the Chinese Academy of Sciences in 2003.

Which brings Yours Truly back to the “Broadly Protective Influenza Vaccine” Patent that is owned by Dr. Jeffery Taubenberger, a “career employee” of the NIH who is now the Acting Director of the NIAID. Yours Truly has written about this scientist in the Health Friday offering of 29 August 2025, cited above in today’s offering. This is the “Universal Influenza Vaccine” that Dr. Taubenberger developed at the NIH: https://www.techtransfer.nih.gov/tech/tab-3388, “Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses”, published 6 July 2020. A screenshot from this page is below:

Note the “intranasally or intramuscularly” in the above statement.

The Patent declaration document for the above “Universal Influenza Vaccine” is here: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369675, filed 21 July 2020. The title of the Patent is the same as that of the NIH TechTransfer information cited above.

All of the foregoing appears to point in the direction of a “universal influenza vaccine” that includes various types of influenza viruses (“swine flu”; Avian influenza; Influenza B); that would require at least three doses of a “vaccine” to have “sufficient protection”; and, that the “delivery methods” of the three doses appears to be 2 intramuscular injections of a modRNA plus cationic lipid nanoparicles “vaccine” to “prime the pump”, plus 1 “booster dose” of an intranasal modRNA plus PHC-nanoparticle “vaccine” to “provide sufficient protection” from infection. And, that this situation is being “influenced”, so to speak, by the “new direction” of the NIAID, led by Acting Director Dr. Jeffery Taubenberger.

One must ask: Why is there so much emphasis on a “universal influenza vaccine” that combines elements of “swine flu” viruses, of various Avian Influenza viruses, and, of the Influenza B virus? Why is there an emphasis on “aged populations” in the Gain-of-Function experiments described above in today’s offering?

THERE. MUST. BE. ACCOUNTABILITY.

THERE. MUST. BE. JUSTICE.

THERE. MUST. BE. TRUTH.

Peace, Good Energy, Respect: PAVACA